

Jaymin B Morjaria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7761229/publications.pdf>

Version: 2024-02-01

38
papers

1,536
citations

471371

17
h-index

330025

37
g-index

38
all docs

38
docs citations

38
times ranked

2013
citing authors

#	ARTICLE	IF	CITATIONS
1	Dupilumab and tezepelumab in severe refractory asthma: new opportunities. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210973.	1.1	6
2	Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection. <i>IDCases</i> , 2021, 25, e01172.	0.4	32
3	Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up. <i>Internal and Emergency Medicine</i> , 2021, 16, 687-696.	1.0	33
4	COPD smokers who switched to e-cigarettes: health outcomes at 5-year follow up. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232096161.	1.1	47
5	Baseline Results of the West London lung cancer screening pilot study – Impact of mobile scanners and dual risk model utilisation. <i>Lung Cancer</i> , 2020, 148, 12-19.	0.9	37
6	Bilateral lower limb weakness: a cerebrovascular consequence of covid-19 or a complication associated with it?. <i>Internal and Emergency Medicine</i> , 2020, 15, 901-905.	1.0	9
7	Symptoms and exacerbations in asthma: an apparent paradox?. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231988438.	1.1	5
8	An evaluation of mepolizumab for the treatment of severe asthma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 491-500.	1.4	5
9	The discovery and development of acclidinium bromide for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 563-577.	2.5	2
10	Treatment of Allergic Rhinitis as a Strategy for Preventing Asthma. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 23.	2.4	35
11	Biologic agents for severe asthma patients: clinical perspectives and implications. <i>Internal and Emergency Medicine</i> , 2018, 13, 155-176.	1.0	13
12	Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880849.	1.0	53
13	Health effects in COPD smokers who switch to electronic cigarettes: a retrospective-prospective 3-year follow-up. <i>International Journal of COPD</i> , 2018, Volume 13, 2533-2542.	0.9	61
14	Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 319-329.	1.9	2
15	Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study. <i>Lung</i> , 2017, 195, 281-288.	1.4	52
16	Asthma phenotypes: do cough and wheeze predict exacerbations in persistent asthma?. <i>European Respiratory Journal</i> , 2017, 50, 1701366.	3.1	13
17	E-cigarettes in patients with COPD: current perspectives. <i>International Journal of COPD</i> , 2017, Volume 12, 3203-3210.	0.9	27
18	Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. <i>European Journal of Clinical Investigation</i> , 2016, 46, 698-706.	1.7	57

#	ARTICLE	IF	CITATIONS
19	Vilanterol trifenate for the treatment of COPD. Expert Review of Respiratory Medicine, 2016, 10, 719-731.	1.0	12
20	Persisting long term benefits of smoking abstinence and reduction in asthmatic smokers who have switched to electronic cigarettes. Discovery Medicine, 2016, 21, 99-108.	0.5	73
21	Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. International Journal of COPD, 2015, 10, 111.	0.9	9
22	<i>Nocardia cyriacigeorgica</i> in an immunocompetent patient. Therapeutic Advances in Respiratory Disease, 2015, 9, 28-30.	1.0	1
23	Bilateral chylothorax: an unusual complication of cervical rib resection. Therapeutic Advances in Chronic Disease, 2015, 6, 29-33.	1.1	3
24	Clinicopharmacological profile of the fixed-dose combination of acclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease, 2015, 9, 56-68.	1.0	2
25	Emerging therapeutic strategies in COPD. Drug Discovery Today, 2015, 20, 371-379.	3.2	17
26	Effect of Smoking Abstinence and Reduction in Asthmatic Smokers Switching to Electronic Cigarettes: Evidence for Harm Reversal. International Journal of Environmental Research and Public Health, 2014, 11, 4965-4977.	1.2	118
27	Pneumothorax: a tale of pain or spontaneity. Therapeutic Advances in Chronic Disease, 2014, 5, 269-273.	1.1	3
28	Autonomic dysregulation: a mechanism of asthma death. European Respiratory Journal, 2014, 44, 1357-1360.	3.1	1
29	Is opiate action in cough due to sedation?. Therapeutic Advances in Chronic Disease, 2014, 5, 200-205.	1.1	10
30	Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Internal and Emergency Medicine, 2014, 9, 537-546.	1.0	141
31	Preventing Progression of Allergic Rhinitis to Asthma. Current Allergy and Asthma Reports, 2014, 14, 412.	2.4	27
32	Airway responsiveness to adenosine after a single dose of fluticasone propionate discriminates asthma from COPD. Pulmonary Pharmacology and Therapeutics, 2014, 27, 70-75.	1.1	3
33	Novel antitussive strategies. Drug Discovery Today, 2013, 18, 380-388.	3.2	9
34	Fluticasone furoate and vilanterol for COPD. Lancet Respiratory Medicine, the, 2013, 1, e21.	5.2	2
35	Efficiency and Safety of an eElectronic cigAreTte (ECLAT) as Tobacco Cigarettes Substitute: A Prospective 12-Month Randomized Control Design Study. PLoS ONE, 2013, 8, e66317.	1.1	576
36	Unusual asthma syndromes and their management. Therapeutic Advances in Chronic Disease, 2011, 2, 249-264.	1.1	6

#	ARTICLE	IF	CITATIONS
37	Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD. Drug Discovery Today, 2010, 15, 396-405.	3.2	32
38	The holistic perspective of chronic obstructive pulmonary disease: doubt some more. Therapeutic Advances in Chronic Disease, 2010, 1, 37-41.	1.1	2